Relmada Therapeutics Announces Completion of Dosing with REL-1017 in Phase 2 Study of Individuals with Treatment Resistant Depression

Relmada Therapeutics Announces Completion of Dosing with REL-1017 in Phase 2 Study of Individuals with Treatment Resistant Depression
REL-1017 is a novel NMDA receptor antagonist in development as a rapidly acting oral agent for the treatment of depressionĀ 

See more here

Comments are closed.